GLP-1 Drugs in Adolescents: What the Approval and Trial Data Actually Cover

Semaglutide received FDA approval for chronic weight management in adolescents aged 12 and older with obesity in 2022, extending a drug class previously studied and approved only in adults — a development with its own dedicated trial evidence and its own set of clinical considerations distinct from adult use.

The Trial Behind the Adolescent Approval

The adolescent approval rests primarily on the STEP TEENS trial, a randomized, placebo-controlled trial specifically enrolling adolescents aged 12-17 with obesity, using the same 2.4mg weekly semaglutide dose studied in adult trials. The trial found substantial mean BMI reduction in the semaglutide group compared to placebo over 68 weeks, with a side effect profile broadly similar in kind to the adult trials, GI symptoms concentrated during titration being the most common. This is genuine, dedicated pediatric trial data, not simply an extrapolation from adult results applied to a younger age group without direct testing.

Why Pediatric-Specific Trials Matter

Drug responses, side effect profiles, and appropriate dosing don't always translate directly from adults to adolescents, particularly for a population still undergoing physical development — which is why a dedicated pediatric trial, rather than simply approving adult dosing for younger patients based on adult data alone, is the standard and more rigorous approach the FDA generally requires before extending an approval to a pediatric population. STEP TEENS fulfilled that requirement specifically for semaglutide in this age range and this specific obesity indication.

Bone and Growth Considerations Specific to Adolescents

Because adolescence is a period of ongoing bone accrual and growth, questions specific to the pediatric population — whether rapid weight loss affects growth trajectory or bone mineral accrual during this developmental window — receive particular attention in adolescent GLP-1 use that don't apply the same way in adults who have already completed growth. Current guidance and the trial data available so far haven't identified a clear adverse signal on growth specifically, but this remains an area of ongoing monitoring given the more limited long-term follow-up duration compared to the extensive adult data.

Psychosocial and Eating Behavior Considerations

The disordered-eating screening considerations discussed for adult GLP-1 use apply with additional weight in adolescents, a population already at elevated risk for developing eating disorders and body image concerns during this developmental stage — pediatric obesity medicine guidelines generally emphasize careful psychosocial evaluation alongside medical appropriateness when considering GLP-1 therapy in this age group specifically.

Practical Takeaway

GLP-1 use in adolescents rests on genuine, dedicated pediatric trial data (STEP TEENS) rather than simply extending adult findings downward in age, and the FDA approval reflects that dedicated evidence base specifically for semaglutide at 12 and older with obesity. Growth, bone development, and psychosocial/eating-behavior considerations carry particular weight in this population given adolescence's unique developmental context, making appropriate use here a decision best made through pediatric obesity medicine specialists familiar with both the drug and these adolescent-specific considerations, rather than a straightforward extension of adult prescribing practice.